Fig. 1From: Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemiaOverall survival for all patients vs. non-responders: Kaplan–Meier, parametric curve fits, and Cox proportional hazards modelBack to article page